Roche Tasmar Relabeling Adds Patient Consent Form Citing Liver Toxicity

The relabeling of Roche's Parkinson's therapy Tasmar (tolcapone) to reflect reports of severe liver toxicity includes a consent form requiring patients to acknowledge that they are risking fatal side effects by taking the drug.